Co-Authors
This is a "connection" page, showing publications co-authored by JEFFREY J MOLLDREM and GHEATH AL-ATRASH.
Connection Strength
4.502
-
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res. 2018 07 15; 24(14):3386-3396.
Score: 0.650
-
Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol. 2012 Dec 01; 189(11):5476-84.
Score: 0.445
-
The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother. 2012 May; 35(4):309-20.
Score: 0.430
-
Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One. 2011; 6(8):e23217.
Score: 0.409
-
Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol. 2011 Feb; 4(1):37-50.
Score: 0.395
-
Immune rage against MAGE unleashed. Blood. 2010 Sep 16; 116(11):1824-5.
Score: 0.384
-
Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE. Br J Haematol. 2010 Sep; 150(6):716-9.
Score: 0.383
-
Immunotherapy of AML. Cancer Treat Res. 2010; 145:237-55.
Score: 0.366
-
Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620.
Score: 0.171
-
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.
Score: 0.121
-
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013 Jan 01; 19(1):247-57.
Score: 0.112
-
Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 2012 Jul 01; 72(13):3153-62.
Score: 0.108
-
An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011 Apr 21; 117(16):4262-72.
Score: 0.099
-
Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy. 2010 Dec; 12(8):1056-62.
Score: 0.096
-
PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One. 2010 Jul 26; 5(7):e11770.
Score: 0.095
-
Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia. Cancer Res Commun. 2024 Mar 25; 4(3):911-918.
Score: 0.061
-
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. Clin Cancer Res. 2023 05 15; 29(10):1938-1951.
Score: 0.058
-
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719.
Score: 0.050
-
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
Score: 0.043
-
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res. 2011 Sep 15; 17(18):5945-52.
Score: 0.026